Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Have you seen the AH price? We are being f'ed with.
What's up with our volume today? Anybody know what it means? Thanks.
Thanks JTFM.
Thanks rg. Let's have a great day tomorrow.
See AH price. Sweet dreams to all my favorite Biosantians.
Hopefully the market will be looking better by Wednesday. Last week looked for any excuse to drag a stock down.
We have weathered the week amazingly well.
Hi Silvr. ANIP isn't part of XBI. You can download the holdings on the site you linked. ANIK is listed but not ANIP.
I never thought of shorts coming from an ETF. Scary thought.
Thanks JTFM. We hit a $70-72 ceiling so many times it seemed like a mirage when we broke through. We have so many strengths that justify the higher pps.
Best of luck to all longs and thanks to you and all regular posters for all the important input.
Thanks for the history JTFM. Very helpful!
Thanks Rg!
Hi Silvr, Someone posts current short data. Is that rgshredder? If so, please weigh in. Thanks!
I'm a little nervous that our pps rose so quickly. Not complaining!
Hi Jeff, I can imagine him answering a question about it on a conference call but I cannot imagine him sharing any information without a PR. Too many people affected. Meanwhile, T for women is back in the news!I
Best of luck. Hit $85 today.
Happiness, if realized.
JTFM, Do you know of any other cases where companies collaborated to provide safety and efficacy data? Must both come from same study? This is very interesting and so overdue!
Same article cited in MEDPAGE. https://www.medpagetoday.com/endocrinology/menopause/81236
Thanks for heads-up on probable news.
Thank you!
JTFM, Thank you for this fabulous summary. You are such an asset to this board!
Hi JTFM (or anyone who knows answer); Please remind me of our nearest term catalyst. Sorry. Lost notes from cc and too busy to dig right now. Thanks.
Hi JTFM, Yes, that would be me. Due to recent approval of Vyleesi the time for our safety data may be here.
Congrats everyone for today's breakthrough.
Here's the news release:
http://www.anipharmaceuticals.com/aboutus_newsmedia_view.php?i=178
Thanks BB! Another launch eases heartburn better than ranitidine!
If that were the case, I think volume would be higher. This is pure muscle.
Hi Easka,
Thank you for sharing the news!
Thank you Silvr.
Thanks JTFM
Down on 150 shares. Please.
Silvr, Thanks for explaining that convoluted story.It would help if companies were required to be more transparent about royalty agreements. Shareholders are often left in the dark.
I'm sure revenue projections were done with generic pricing. We are, after all, seeking a generic version of acthar gel.
With what's been accomplished already I am confident that Art's got this.
Very negative for Mallincrodt. Not for ANIP. We have no history of overcharging or unscrupulous business practice. Not sure what you mean.
Hi Silvr, Just saw that! Coming back to $72 today was a very good sign. Thanks for the Yescarta update too.
Looks like shorts know good news is coming.
Hi Jeff. My post about the corti drug also known as acthar gel? Saw the Mallincrodt headline yesterday in Marketwatch.
From the article:
The suit "seeks to hold unlawful and set aside the Agency's recent unjustified decision to require that Mallinckrodt change the base date average manufacturer price (AMP) used to calculate Medicaid drug rebates for Acthar(R) Gel (repository corticotropin injection)," the company said in a statement.
HHS and CMS are trying to reduce cost of this drug that has for years been on the list of wildly expensive drugs.
AMP:https://definitions.uslegal.com/a/average-manufacturer-price-amp-health-care/
AMP changed under ACA. 2012 was when the Supreme Court decided that the ACA had teeth.
From the article:
The CMS decision reverses without explanation a 2012 approval of the calculation of Medicaid rebates for the gel, said Mallinckrodt. "We are disappointed with the action taken by CMS. "With our repeated attempts to engage both HHS and CMS in productive discussions ultimately rebuffed, we find ourselves with no other choice than to vigorously defend our position, through the courts, that Medicaid patients should have access to this important therapy," said Mark Casey, general counsel at Mallinckrodt.
JMHO. I think Art saw the writing on the wall about a need for a generic version.
If you are looking to be brought up to speed on the senior convertible notes, I am not your news source. Please read posts by JTFM and Silvr. I emailed the company on Monday and have yet to hear an answer.
Best, J
Me too.
$500m is what they have already invested. The article does not state the cost to modernize. Confusing wording.
"The move would eliminate Medicaid sales of the gel and undermine the company's effort to build on its existing investment of more than $500 million to modernize the gel."
My read is that the cost per prescription is objectionable.
Sounds positive and robotic! Thanks for the technical assistance lol.
Bad news for Mallinckrodt. Good news for the company with the generic version of acthar gel.
https://www.marketwatch.com/story/mallinckrodt-files-suit-against-hhs-and-cmms-over-medicaid-patient-access-to-acthar-gel-2019-05-21-7912827